SARS-CoV-2

Where the papers sit

32 papers from the last 6 months study SARS-CoV-2 directly · updated from PubMed 8 Oct 2026

• Broad-Spectrum Antiviral Discovery

  Antiviral discovery is moving from broad screening toward structure-guided and computationally prioritized compounds. Mpro and helicase inhibition recur alongside repurposed ALK inhibitors, alkaloids, flavonoids, pyrimidine scaffolds, and designed nucleoside analogs. ACE2-PNA conjugates add targeted intracellular delivery, while Hypericum compounds combine antiviral, antioxidant, and immunomodulatory activity. IC50, replication assays, docking, and machine learning prioritize candidates, but clinical efficacy remains open.

  11 papers · 34.4%

• SARS-CoV-2 Immune Protection

  Antigenic breadth and durable neutralization are recurring goals, pursued through intranasal adenovirus vaccines, tandem or divergent RBD immunogens, and monoclonal antibodies such as VYD2311. Natural infection and vaccination are compared through nucleocapsid- and spike-specific isotypes, while standardized assays improve measurement of T-cell and Treg responses. Checkpoint inhibition and dual-target immunization extend the focus beyond neutralizing antibody alone. The set is moving toward broader, longer-lasting mucosal and cellular protection, although inflammatory lung pathology remains a separate mechanistic thread.

  9 papers · 28.1%

• Respiratory Virus Infection

  Exposure route appears to shape respiratory infection patterns more strongly than inoculum dose. Upper-respiratory-tract mycobiome shifts add a host-ecology dimension to infection studies. Genomic surveillance tracks Omicron-era circulation, while cyclophilin inhibitors are being optimized for broader antiviral coverage. The shared focus is respiratory-virus transmission, host context, and control rather than a single intervention.

  4 papers · 12.5%

• CRISPR Diagnostic Engineering

  CRISPR-Cas12a diagnostics are being tuned for rapid, one-pot nucleic-acid detection. The key bottleneck is matching crRNA scaffold, amplification, and cleavage kinetics to improve sensitivity and reproducibility. G4 DNAzyme integration broadens the platform toward nucleic-acid and non-nucleic-acid targets. The work remains focused on assay engineering rather than clinical validation or therapeutic use.

  2 papers · 6.2%

• Others — COVID-19 Vaccination and Prevention

  COVID-19 vaccination work centers on access, booster protection, and strategies that reduce hospitalization or death in vulnerable groups. Rural availability in sub-Saharan Africa remains a barrier, while mRNA formulations are being extended to multicomponent influenza–SARS-CoV-2 vaccines. Evidence spans systematic reviews, comparative strategies, and immune-mediated inflammatory disease populations. Other entries address iron-rich cerebral thrombi or a preclinical 3CL protease inhibitor, leaving no single research direction.

  6 papers · 18.8%